ExpreS2ion has a streamlined company structure. ExpreS2ion Biotech Holding AB is the Swedish entity listed on Nasdaq First North Growth Market since 2016. ExpreS2ion Biotechnologies ApS is the operational entity, with offices and labs in the Scion DTU Science park just north of Copenhagen, Denmark, and was established in 2010. AdaptVac is a joint venture established in 2017 together with a group of scientists from the Institute of Immunology and Microbiology at the University of Copenhagen. The scientists own their part of AdaptVac through a joint holding company named NextGen vaccines ApS.
Note: The Company’s ownership stake in AdaptVac is reduced from 50 percent to 34 percent upon exercise of the option to in-license the breast cancer vaccine candidate AV001/Her2-cVLP. NextGen vaccines will then own 66% of AdaptVac.